Division of BridgeBio Pharma Inc.
Latest From Navire Pharma
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- BridgeBio Pharma Inc.
- Senior Management
Shafique Virani, MD, CEO
Cameron Turtle, VP, Bus. Dev. & Operations
Uma Sinha, PhD, CSO
- Contact Info
Phone: (650) 391-9740
421 Kipling St.
Palo Alto, CA 94301
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.